跳至主要内容
临床试验/NCT00281970
NCT00281970已完成2 期

Phase II Trial of Weekly Docetaxel (Taxotere®) and Monthly Cisplatin Chemotherapy as Adjuvant Treatment for Patients With Completely Resected Non-small Cell Lung Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins5 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2004年8月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
50
试验地点
5
主要终点
Total cisplatin dose

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy drugs after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well giving docetaxel together with cisplatin works in treating patients with stage I, stage II, or stage III non-small cell lung cancer that has been completely removed by surgery.

详细描述

OBJECTIVES:

Primary

  • Compare the efficacy and safety of a new dosing schedule and dosing level of docetaxel and cisplatin with the chemotherapy regimens used in the International Adjuvant Lung Cancer Trial (IALT) in patients with completely resected stage IA-IIIB non-small cell lung cancer.

Secondary

  • Explore the relationship of time to recurrence, disease-free survival, and overall survival of these patients with levels of circulating DNA and proteomic analysis of serum.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Total cisplatin dose

次要结局

  • Toxicity
  • Overall survival
  • Disease-free survival

研究者

申办方类型
Other
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验